{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T10:50:51Z","timestamp":1788691851140,"version":"build-2803163510"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Rabies monoclonal antibody (mAb) is a life-saving immune-biological for postexposure prophylaxis (PEP) in all Category III animal exposures. A novel cocktail of mAbs derived using recombinant DNA technology is presently available for usage. The WHO recommends monitoring the clinical use and outcomes of mAb products.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>An open-label, postmarketing study was conducted at the anti-rabies clinic in the southern part of India. PEP was provided to all the study participants per the national guidelines. All the subjects were assessed for any adverse events (AEs) following PEP up to 35 days; if any, were treated free of cost at the study center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The present study included 309 subjects across all age groups, 59.2% were adults, 33.3% of children, and 7.5% elderly. Majority of the patients were exposed to dogs (89.6%) and most of them had lacerations (86.3%) in different parts of their body. A total of 19 (6.2%) AEs were reported. All the AEs were local reactions, namely pain (2.6%), erythema (1.4%), tenderness (1%), induration (0.6%), and swelling (0.6%). All reported AEs were mild (Grade 1 severity) and resolved completely with symptomatic treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The novel cocktail of mAbs was safe for PEP in Category III animal exposures across all the age groups and supports its continued and improved usage for Universal Health Coverage to prevent rabies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jgid.jgid_71_24","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T10:00:10Z","timestamp":1729504810000},"page":"140-144","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Safety Evaluation of the Novel Cocktail of Monoclonal Antibodies for Postexposure Prophylaxis in Category III Animal Exposures"],"prefix":"10.4103","volume":"16","author":[{"given":"Ravish Haradanahalli","family":"Shankaraiah","sequence":"first","affiliation":[{"name":"Department of Community Medicine, Kempegowda Institute of Medical Sciences, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N. R. Ramesh","family":"Masthi","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Kempegowda Institute of Medical Sciences, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. K.","family":"Poornima","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Kempegowda Institute of Medical Sciences, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinitha","family":"Kiruffi","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Kempegowda Institute of Medical Sciences, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sowmyashree","sequence":"additional","affiliation":[{"name":"Department of Community Medicine, Kempegowda Institute of Medical Sciences, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trayambak","family":"Dutta","sequence":"additional","affiliation":[{"name":"Zydus Lifesciences Ltd., Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Mahajan","sequence":"additional","affiliation":[{"name":"Zydus Lifesciences Ltd., Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Desai","sequence":"additional","affiliation":[{"name":"Zydus Lifesciences Ltd., Ahmedabad, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"key":"R1-20241221","first-page":"201","article-title":"Rabies vaccines: WHO position paper No. 16","volume":"93","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"key":"R3-20241221","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/tropicalmed2020005","article-title":"Four thousand years of concepts relating to rabies in animals and humans, its prevention and its cure","volume":"2","author":"Tarantola","year":"2017","journal-title":"Trop Med Infect Dis"},{"key":"R4-20241221","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijid.2005.10.007","article-title":"Assessing the burden of human rabies in India: Results of a national multi-center epidemiological survey","volume":"11","author":"Sudarshan","year":"2007","journal-title":"Int J Infect Dis"},{"key":"R5-20241221","doi-asserted-by":"crossref","first-page":"e780","DOI":"10.1016\/S2214-109X(16)30245-5","article-title":"2016: The beginning of the end of rabies?","volume":"4","author":"Abela-Ridder","year":"2016","journal-title":"Lancet Glob Health"},{"key":"R9-20241221","first-page":"e52163","article-title":"Real-world safety of twinrab, the world\u2019s first novel cocktail of rabies monoclonal antibodies, in a clinical setting","volume":"16","author":"Manna","year":"2024","journal-title":"Cureus"},{"key":"R12-20241221","doi-asserted-by":"crossref","first-page":"48","DOI":"10.3390\/tropicalmed2030048","article-title":"In vivo efficacy of a cocktail of human monoclonal antibodies (CL184) against diverse North American bat rabies virus variants","volume":"2","author":"Franka","year":"2017","journal-title":"Trop Med Infect Dis"},{"key":"R13-20241221","doi-asserted-by":"crossref","first-page":"e542","DOI":"10.1371\/journal.pntd.0000542","article-title":"Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans","volume":"3","author":"M\u00fcller","year":"2009","journal-title":"PLoS Negl Trop Dis"},{"key":"R14-20241221","doi-asserted-by":"crossref","first-page":"2026713","DOI":"10.1080\/21645515.2022.2026713","article-title":"Advances in the progress of monoclonal antibodies for rabies","volume":"18","author":"Fan","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"R15-20241221","doi-asserted-by":"crossref","first-page":"9403","DOI":"10.1038\/s41598-022-13527-0","article-title":"A cocktail of human monoclonal antibodies broadly neutralizes North American rabies virus variants as a promising candidate for rabies post-exposure prophylaxis","volume":"12","author":"Ejemel","year":"2022","journal-title":"Sci Rep"},{"key":"R16-20241221","doi-asserted-by":"crossref","first-page":"e2722","DOI":"10.1093\/cid\/ciaa779","article-title":"A phase 3, randomized, open-label, noninferiority trial evaluating anti-rabies monoclonal antibody cocktail (Twinrab\u2122) against human rabies immunoglobulin (HRIG)","volume":"73","author":"Kansagra","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R17-20241221","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/cid\/cix791","article-title":"Comparison of a novel human rabies monoclonal antibody to human rabies immunoglobulin for postexposure prophylaxis: A phase 2\/3, randomized, single-blind, noninferiority, controlled study","volume":"66","author":"Gogtay","year":"2018","journal-title":"Clin Infect Dis"},{"key":"R18-20241221","doi-asserted-by":"crossref","first-page":"2081024","DOI":"10.1080\/21645515.2022.2081024","article-title":"Safety and clinical efficacy of human rabies immunoglobulin in post exposure prophylaxis for category III animal exposures","volume":"18","author":"Haradanhalli","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"R19-20241221","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1080\/21645515.2020.1854000","article-title":"Safety and efficacy of rabies immunoglobulin in pediatric patients with suspected exposure","volume":"17","author":"Hobart-Porter","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"R20-20241221","first-page":"63","article-title":"Comparison of safety profile of equine and human rabies immunoglobulin in children below 15 years, in a tertiary care hospital of Odisha \u2013 An observational study","volume":"52","author":"Priyadarsini","year":"2020","journal-title":"J Commun Dis"},{"key":"R21-20241221","doi-asserted-by":"crossref","first-page":"100207","DOI":"10.1016\/j.lansea.2023.100207","article-title":"Active safety surveillance of rabies monoclonal antibody and rabies vaccine in patients with category III potential rabies exposure","volume":"14","author":"Kang","year":"2023","journal-title":"Lancet Reg Health Southeast Asia"}],"container-title":["Journal of Global Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jgid.jgid_71_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:37:00Z","timestamp":1787067420000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jgid.jgid_71_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/jgid.jgid_71_24","relation":{},"ISSN":["0974-777X","0974-8245"],"issn-type":[{"value":"0974-777X","type":"print"},{"value":"0974-8245","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"2024-03-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-26","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}